TRIP13 and head and neck cancer: As the first research indicated that TRIP13 acts as an oncogene, Banerjee and his colleagues utilized mass spectrometry and Co-IP to explore how TRIP13 promotes head and neck cancer progression, and they found that TRIP13 promotes non-homologous end joining (NHEJ) and induces chemoresistance5.